Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

FromJAMA Ophthalmology Author Interviews


Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema

FromJAMA Ophthalmology Author Interviews

ratings:
Length:
13 minutes
Released:
Feb 2, 2023
Format:
Podcast episode

Description

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
Released:
Feb 2, 2023
Format:
Podcast episode

Titles in the series (100)

Interviews with authors of articles from JAMA Ophthalmology. JAMA Ophthalmology, published continuously since 1869, is an international, peer-reviewed ophthalmology and visual science journal. Covering research, science, & clinical practice in ophthalmology and vision science.